Skip to content
  • Wednesday, 28 October 2026
  • 1:20 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide
Pharmaceutical R&D

Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide

Teuku Ryan Jun 6, 2026 0

Parabilis Medicines, a promising biotechnology firm, is strategically positioning itself for a significant public market debut, announcing its intention to…

Read More
A Beginner’s Guide to Setting Up Claude Code for High Performance Agentic ProgrammingFive Fun Projects Using Claude Code for Advanced Software Development MasteryA common vape flavoring may disrupt early embryo developmentTWiV 1287: Ancient herpesviruses and modern dementia
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
The oral exposure challenge in PROTACs: What drug developers need to solve earlyThe Silence Broken: How Brain-Computer Interfaces are Restoring the Human Voice for Those Paralyzed by ALSESMO26: KEYNOTE-C93 Backs Chemo-Free Keytruda in dMMR Endometrial CancerThe Discovery of REM-like Sleep in Jumping Spiders Challenges Traditional Views of Animal Consciousness
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
The oral exposure challenge in PROTACs: What drug developers need to solve early
Lana Keisha Oct 28, 2026
Environmental & Analytical Chemistry
The Silence Broken: How Brain-Computer Interfaces are Restoring the Human Voice for Those Paralyzed by ALS
Abdurrohim Arsyad Oct 28, 2026
Pharmaceutical R&D
ESMO26: KEYNOTE-C93 Backs Chemo-Free Keytruda in dMMR Endometrial Cancer
Teuku Ryan Oct 28, 2026
Molecular & Cell Biology
The Discovery of REM-like Sleep in Jumping Spiders Challenges Traditional Views of Animal Consciousness
Angie Faith Oct 28, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ